纳米材料治疗具核梭杆菌促进的结直肠癌研究进展

doi:10.13345/j.cjb.220811

科微学术

生物工程学报

首页 > 过刊浏览>2023年第39卷第9期 >3670-3680. DOI:10.13345/j.cjb.220811

PDF HTML阅读 XML下载导出引用引用提醒

纳米材料治疗具核梭杆菌促进的结直肠癌研究进展
DOI:
                        10.13345/j.cjb.220811
                    
CSTR:
                        32114.14.j.cjb.220811
                    
作者:
                        王杭王杭
中国医学科学院北京协和医学院 放射医学研究所, 天津 300192
在期刊界中查找
在百度中查找
在本站中查找
侯小雪侯小雪
中国医学科学院北京协和医学院 放射医学研究所, 天津 300192
在期刊界中查找
在百度中查找
在本站中查找
刘鉴峰刘鉴峰
中国医学科学院北京协和医学院 放射医学研究所, 天津 300192
在期刊界中查找
在百度中查找
在本站中查找
杨翠红杨翠红
中国医学科学院北京协和医学院 放射医学研究所, 天津 300192
在期刊界中查找
在百度中查找
在本站中查找

                    
作者单位:
作者简介:
通讯作者:
中图分类号:
基金项目:国家自然科学基金(31771085)；天津市自然科学基金杰出青年科学基金(18JCJQJC47300，19JCJQJC62200)

Advances on the treatment of Fusobacterium nucleatum-promoted colorectal cancers using nanomaterials

Author:

WANG Hang
WANG Hang
Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
在期刊界中查找
在百度中查找
在本站中查找
HOU Xiaoxue
HOU Xiaoxue
Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
在期刊界中查找
在百度中查找
在本站中查找
LIU Jianfeng
LIU Jianfeng
Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
在期刊界中查找
在百度中查找
在本站中查找
YANG Cuihong
YANG Cuihong
Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
在期刊界中查找
在百度中查找
在本站中查找

Affiliation:

Fund Project:

摘要

图/表

访问统计

参考文献 [45]

相似文献 [20]

引证文献

资源附件

文章评论

摘要:

具核梭杆菌(Fusobacterium nucleatum, Fn)是一种口腔厌氧菌，最近被发现在人类结直肠癌(colorectal cancer, CRC)细胞表面聚集，其富集程度与癌症治疗预后呈高度负相关。大量研究表明，Fn参与CRC的发生与发展过程，Fn与肿瘤微环境中多种组分相互作用从而增强肿瘤的耐药性。近年来，开始有研究利用纳米材料抑制Fn在肿瘤部位的增殖或通过直接靶向Fn治疗CRC。因此，本综述一方面将对近年来Fn在CRC中促肿瘤的机制进行梳理总结，另一方面将归纳整理不同纳米材料应用于Fn相关CRC治疗的最新研究进展，最后对纳米材料在Fn介导的CRC治疗中的应用前景进行了展望。

关键词:具核梭杆菌;结直肠癌;纳米材料;肿瘤治疗

Abstract:

Fusobacterium nucleatum (Fn) is an oral anaerobic bacterium that has recently been found to colonize on the surface of colorectal cancer cells in humans, and its degree of enrichment is highly negatively correlated with the prognosis of tumor treatment. Numerous studies have shown that Fn is involved in the occurrence and development of colorectal cancer (CRC), and Fn interacts with multiple components in the tumor microenvironment to increase tumor resistance. In recent years, researchers have begun using nanomedicine to inhibit Fn’s proliferation at the tumor site or directly target Fn to treat CRC. This review summarizes the mechanism of Fn in promoting CRC and the latest research progress on Fn-related CRC therapy using different nanomaterials. Finally, the applications perspective of nanomaterials in Fn-promoted CRC therapy was prospected.

Key words:Fusobacterium nucleatum (Fn);colorectal cancer;nanomaterials;cancer therapy

参考文献

[1] BRENNAN CA, GARRETT WS. Gut microbiota, inflammation, and colorectal cancer[J]. Annual Review of Microbiology, 2016, 70:395-411.

[2] LI YY, GE QX, CAO J, ZHOU YJ, DU YL, SHEN B, WAN YJ Y, NIE YQ. Association of Fusobacterium nucleatum infection with colorectal cancer in Chinese patients[J]. World Journal of Gastroenterology, 2016, 22(11):3227.

[3] CASTELLARIN M, WARREN RL, DOUGLAS FREEMAN J, DREOLINI L, KRZYWINSKI M, STRAUSS J, BARNES R, WATSON P, ALLEN-VERCOE E, MOORE RA, HOLT RA. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma[J]. Genome Research, 2012, 22(2):299-306.

[4] MIMA K, NISHIHARA R, QIAN ZR, CAO Y, SUKAWA Y, NOWAK JA, YANG JH, DOU RX, MASUGI Y, SONG MY, KOSTIC AD, GIANNAKIS M, BULLMAN S, MILNER DA, BABA H, GIOVANNUCCI EL, GARRAWAY LA, FREEMAN GJ, DRANOFF G, GARRETT WS, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis[J]. Gut, 2016, 65(12):1973-1980.

[5] SALVUCCI M, CRAWFORD N, STOTT K, BULLMAN S, LONGLEY DB, PREHN JHM. Patients with mesenchymal tumours and high Fusobacteriales prevalence have worse prognosis in colorectal cancer (CRC)[J]. Gut, 2022, 71(8):1600-1612.

[6] ABED J, MAALOUF N, MANSON AL, EARL AM, PARHI L, EMGÅRD JEM, KLUTSTEIN M, TAYEB S, ALMOGY G, ATLAN KA, CHAUSHU S, ISRAELI E, MANDELBOIM O, GARRETT WS, BACHRACH G. Colon cancer-associated Fusobacterium nucleatum may originate from the oral cavity and reach colon tumors via the circulatory system[J]. Frontiers in Cellular and Infection Microbiology, 2020, 10:400.

[7] COPPENHAGEN-GLAZER S, SOL A, ABED J, NAOR R, ZHANG X, HAN YW, BACHRACH G. Fap2 of Fusobacterium nucleatum is a galactose-inhibitable adhesin involved in coaggregation, cell adhesion, and preterm birth[J]. Infection and Immunity, 2015, 83(3):1104-1113.

[8] ABED J, EMGÅRD JEM, ZAMIR G, FAROJA M, ALMOGY G, GRENOV A, SOL A, NAOR R, PIKARSKY E, ATLAN KA, MELLUL A, CHAUSHU S, MANSON AL, EARL AM, OU N, BRENNAN CA, GARRETT WS, BACHRACH G. Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed gal-GalNAc[J]. Cell Host & Microbe, 2016, 20(2):215-225.

[9] BULLMAN S, PEDAMALLU CS, SICINSKA E, CLANCY TE, ZHANG X, CAI D, NEUBERG D, HUANG K, GUEVARA F, NELSON T, CHIPASHVILI O, HAGAN T, WALKER M, RAMACHANDRAN A, DIOSDADO B, SERNA G, MULET N, LANDOLFI S, RAMON Y CAJAL S, FASANI R, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer[J]. Science, 2017, 358(6369):1443-1448.

[10] MENG Q, GAO QQ, MEHRAZARIN S, TANGWANICHGAPONG K, WANG Y, HUANG YM, PAN YT, ROBINSON S, LIU ZW, ZANGIABADI A, LUX R, PAPAPANOU PN, GUO XE, WANG H, BERCHOWITZ LE, HAN YW. Fusobacterium nucleatum secretes amyloid-like FadA to enhance pathogenicity[J]. EMBO Reports, 2021, 22(7):e52891.

[11] LI X, HUANG JP, YU TT, FANG XT, LOU LQ, XIN SJ, JI L, JIANG FZ, LOU YL. Fusobacterium nucleatum promotes the progression of colorectal cancer through Cdk5-activated Wnt/β-catenin signaling[J]. Frontiers in Microbiology, 2021, 11:545251.

[12] GUO P, TIAN ZB, KONG XJ, YANG L, SHAN XZ, DONG BZ, DING XL, JING X, JIANG C, JIANG N, YU YN. FadA promotes DNA damage and progression of Fusobacterium nucleatum-induced colorectal cancer through up-regulation of chk2[J]. Journal of Experimental & Clinical Cancer Research, 2020, 39(1):202.

[13] GUR C, IBRAHIM Y, ISAACSON B, YAMIN R, ABED J, GAMLIEL M, ENK J, BAR-ON Y, STANIETSKY-KAYNAN N, COPPENHAGEN- GLAZER S, SHUSSMAN N, ALMOGY G, CUAPIO A, HOFER E, MEVORACH D, TABIB A, ORTENBERG R, MARKEL G, MIKLIĆ K, JONJIC S, et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack[J]. Immunity, 2015, 42(2):344-355.

[14] YANG YZ, WENG WH, PENG JJ, HONG LM, YANG L, TOIYAMA Y, GAO RY, LIU MF, YIN MM, PAN C, LI H, GUO BM, ZHU QC, WEI Q, MOYER MP, WANG P, CAI SJ, GOEL A, QIN HL, MA YL. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating Toll-like receptor 4 signaling to nuclear factor–κB, and up-regulating expression of microRNA-21[J]. Gastroenterology, 2017, 152(4):851-866.e24.

[15] SANTAOLALLA R, SUSSMAN DA, RUIZ JR, DAVIES JM, PASTORINI C, ESPAÑA CL, SOTOLONGO J, BURLINGAME O, BEJARANO PA, PHILIP S, AHMED MM, KO J, DIRISINA R, BARRETT TA, SHANG LM, LIRA SA, FUKATA M, ABREU MT. TLR4 activates the β-catenin pathway to cause intestinal neoplasia[J]. PLoS One, 2013, 8(5):e63298.

[16] OKITA Y, KOI M, TAKEDA K, ROSS R, MUKHERJEE B, KOEPPE E, STOFFEL EM, GALANKO JA, McCOY AN, KEKU TO, OKUGAWA Y, KITAJIMA T, TOIYAMA Y, MARTENS E, CARETHERS JM. Fusobacterium nucleatum infection correlates with two types of microsatellite alterations in colorectal cancer and triggers DNA damage[J]. Gut Pathogens, 2020, 12(1):1-5.

[17] GUO S, CHEN J, CHEN F, ZENG Q, LIU WL, ZHANG G. Exosomes derived from Fusobacterium nucleatum-infected colorectal cancer cells facilitate tumour metastasis by selectively carrying miR-1246/92b-3p/27a-3p and CXCL16.[J]. Gut, 2021, 70:1507-1519.

[18] XU CC, FAN LN, LIN YF, SHEN WY, QI YD, ZHANG Y, CHEN ZH, WANG L, LONG YQ, HOU TY, SI JM, CHEN SJ. Fusobacterium nucleatum promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization[J]. Gut Microbes, 2021, 13(1):1980347.

[19] ZHANG Y, ZHANG L, ZHENG S, LI MJ, XU CC, JIA D, QI YD, HOU TY, WANG L, WANG BY, LI AQ, CHEN SJ, SI JM, ZHUO W. Fusobacterium nucleatum promotes colorectal cancer cells adhesion to endothelial cells and facilitates extravasation and metastasis by inducing ALPK1/NF-κB/ICAM1 axis[J]. Gut Microbes, 2022, 14(1):2038852.

[20] CHEN SJ, SU TT, ZHANG Y, LEE A, HE JM, GE QW, WANG L, SI JM, ZHUO W, WANG LJ. Fusobacterium nucleatum promotes colorectal cancer metastasis by modulating KRT7-AS/KRT7[J]. Gut Microbes, 2020, 11(3):511-525.

[21] GAINES S, SHAO C, HYMAN N, ALVERDY JC. Gut microbiome influences on anastomotic leak and recurrence rates following colorectal cancer surgery[J]. British Journal of Surgery, 2018, 105(2):e131-e141.

[22] DAHAN L, SADOK A, FORMENTO JL, SEITZ JF, KOVACIC H. Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines[J]. British Journal of Pharmacology, 2009, 158(2):610-620.

[23] YU T, GUO FF, YU YN, SUN TT, MA D, HAN JX, QIAN Y, KRYCZEK I, SUN DF, NAGARSHETH N, CHEN YX, CHEN HY, HONG J, ZOU WP, FANG JY. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy[J]. Cell, 2017, 170(3):548-563.e16.

[24] ZHANG S, YANG YZ, WENG WH, GUO BM, CAI GX, MA YL, CAI SJ. Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer[J]. Journal of Experimental & Clinical Cancer Research, 2019, 38(1):1-13.

[25] KARASAWA H, MIURA K, FUJIBUCHI W, ISHIDA K, KANEKO N, KINOUCHI M, OKABE M, ANDO T, MURATA Y, SASAKI H, TAKAMI K, YAMAMURA A, SHIBATA C, SASAKI I. Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells[J]. Cancer Science, 2009, 100(5):903-913.

[26] BRENNAN CA, NAKATSU G, GALLINI COMEAU CA, DREW DA, GLICKMAN JN, SCHOEN RE, CHAN AT, GARRETT WS. Aspirin modulation of the colorectal cancer-associated microbe Fusobacterium nucleatum[J]. mBio, 2021, 12(2):e00547-21.

[27] WANG LJ, ZHANG RQ, YU LL, XIAO JR, ZHOU X, LI XX, SONG PG, LI X. Aspirin use and common cancer risk:a meta-analysis of cohort studies and randomized controlled trials[J]. Frontiers in Oncology, 2021, 11:690219.

[28] PARHI L, ALON-MAIMON T, SOL A, NEJMAN D, SHHADEH A, FAINSOD-LEVI T, YAJUK O, ISAACSON B, ABED J, MAALOUF N, NISSAN A, SANDBANK J, YEHUDA-SHNAIDMAN E, PONATH F, VOGEL J, MANDELBOIM O, GRANOT Z, STRAUSSMAN R, BACHRACH G. Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression[J]. Nature Communications, 2020, 11:3259.

[29] MIHAI MM, ION A, GIURCĂNEANU C, NIȚIPIR C, POPA AM, CHIFIRIUC MC, POPA MI, ŘÍČAŘ J, POPA LG, SÂRBU I, LAZĂR V. The impact of long-term antibiotic therapy of cutaneous adverse reactions to EGFR inhibitors in colorectal cancer patients[J]. Journal of Clinical Medicine, 2021, 10(15):3219.

[30] WEI GQ, WANG Y, YANG G, WANG Y, JU R. Recent progress in nanomedicine for enhanced cancer chemotherapy[J]. Theranostics, 2021, 11(13):6370-6392.

[31] TANG SH, ZHENG J. Antibacterial activity of silver nanoparticles:structural effects[J]. Advanced Healthcare Materials, 2018, 7(13):1701503.

[32] ABBAS B, AZAD K, ROGHAYEH G. Evaluation of antibacterial properties of nano silver Iranian MTA against Fusobacterium nucleatum[J]. European Journal of Experimental Biology, 2013, 3(6):88-94

[33] HAIDARI H, BRIGHT R, KOPECKI Z, ZILM PS, GARG S, COWIN AJ, VASILEV K, GOSWAMI N. Polycationic silver nanoclusters comprising nanoreservoirs of Ag⁺ ions with high antimicrobial and antibiofilm activity[J]. ACS Applied Materials & Interfaces, 2022, 14(1):390-403.

[34] XU L, WANG YY, HUANG J, CHEN CY, WANG ZX, XIE H. Silver nanoparticles:synthesis, medical applications and biosafety[J]. Theranostics, 2020, 10(20):8996-9031.

[35] LIU HY, YANG J, YAN XJ, LI CQ, ELSABAHY M, CHEN L, YANG YW, GAO H. A dendritic polyamidoamine supramolecular system composed of pillar[5]arene and azobenzene for targeting drug-resistant colon cancer[J]. Journal of Materials Chemistry B, 2021, 9(46):9594-9605.

[36] YAN XJ, MA FH, CHEN QX, GOU XB, LI XH, ZHANG LW, GAO H. Construction of size-transformable supramolecular nano-platform against drug-resistant colorectal cancer caused by Fusobacterium nucleatum[J]. Chemical Engineering Journal, 2022, 450:137605.

[37] ZHENG DW, DONG X, PAN P, CHEN KW, FAN JX, CHENG SX, ZHANG XZ. Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy[J]. Nature Biomedical Engineering, 2019, 3(9):717-728.

[38] DONG X, PAN P, ZHENG DW, BAO P, ZENG X, ZHANG XZ. Bioinorganic hybrid bacteriophage for modulation of intestinal microbiota to remodel tumor-immune microenvironment against colorectal cancer[J]. Science Advances, 2020, 6(20):eaba1590.

[39] KILLEEN SD, WANG JH, ANDREWS EJ, REDMOND HP. Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-κB-dependent activation of the urokinase plasminogen activator system[J]. British Journal of Cancer, 2009, 100(10):1589-1602.

[40] SONG WT, TIRUTHANI K, WANG Y, SHEN LM, HU MY, DOROSHEVA O, QIU KY, KINGHORN KA, LIU RH, HUANG L. Trapping of lipopolysaccharide to promote immunotherapy against colorectal cancer and attenuate liver metastasis[J]. Advanced Materials, 2018, 30(52):1805007.

[41] TERNES D, TSENKOVA M, POZDEEV VI, MEYERS M, KONCINA E, ATATRI S, SCHMITZ M, KARTA J, SCHMOETTEN M, HEINKEN A, RODRIGUEZ F, DELBROUCK C, GAIGNEAUX A, GINOLHAC A, DAN NGUYEN TT, GRANDMOUGIN L, FRACHET-BOUR A, MARTIN-GALLAUSIAUX C, PACHECO M, NEUBERGER-CASTILLO L, et al. The gut microbial metabolite formate exacerbates colorectal cancer progression[J]. Nature Metabolism, 2022, 4(4):458-475.

[42] YANG CH, REN CH, ZHOU J, LIU JJ, ZHANG YM, HUANG F, DING D, XU B, LIU JF. Dual fluorescent- and isotopic-labelled self-assembling vancomycin for in vivo imaging of bacterial infections[J]. Angewandte Chemie International Edition, 2017, 56(9):2356-2360.

[43] YANG CH, HU F, ZHANG X, REN CH, HUANG F, LIU JJ, ZHANG YM, YANG LJ, GAO Y, LIU B, LIU JF. Combating bacterial infection by in situ self-assembly of AIEgen-peptide conjugate[J]. Biomaterials, 2020, 244:119972.

[44] CAO HM, GAO Y, JIA HX, ZHANG LP, LIU JJ, MU GN, GUI H, WANG YB, YANG CH, LIU JF. Macrophage-membrane-camouflaged nonviral gene vectors for the treatment of multidrug-resistant bacterial sepsis[J]. Nano Letters, 2022, 22(19):7882-7891.

[45] WANG ZL, YANG CH, ZHANG H, GAO Y, XIAO M, WANG ZY, YANG LJ, ZHANG JM, REN CH, LIU JF. In situ transformable supramolecular nanomedicine targeted activating hippo pathway for triple-negative breast cancer growth and metastasis inhibition[J]. ACS Nano, 2022, 16(9):14644-14657.